Fig. 1
From: Glial activation and inflammation along the Alzheimer’s disease continuum
Between-group CSF immune marker comparisons based on clinical staging. Fig. text: The Y-axis with sTREM2 (a), MCP-1 (b), fractalkine (d), and clusterin (e) reported as CSF concentration in nanograms per milliliter, while the Y-axis for YKL-40 (c) are residuals standardized for age. Error bars are shown as mean and 95% confidence interval (CI). Abbreviation: Ctr: healthy controls (n = 36), SCD: CSF Aβ42+ subjects with subjective cognitive decline (n = 19), MCI: CSF Aβ42+ subjects with mild cognitive impairment (n = 39), Dem: Aβ42+ subjects with Alzheimer’s disease dementia (n = 27). Statistically significant differences are marked with asterisks, where * indicates p < .05, ** indicates p < .01, and *** indicates p < .001